High-flow oxygen via oxygenating mouthguard in short upper gastrointestinal endoscopy: A randomised controlled trial

Table 4 Primary and secondary end points for the intention-to-treat analysis end point (n, %)

End point		SNC (n = 154)	HFMG (n = 138)	P value
Primary endpoint
	SpO2 < 90% of any duration	34, 22.1%	6, 4.4%	< 0.001
Secondary endpoint
	Lowest SpO2 (median, IQR)	95%, 91% to 99%	98%, 96.5% to 99.5%	< 0.001
	Any episode of hypoxaemia	74, 48.1%	26, 18.8%	< 0.001
	SpO2 90%-94% of any duration	40, 26.0%	20, 14.5%	0.015
	SpO2 76%-89% of any duration	28, 18.2%	6, 4.3%	< 0.001
	SpO2 ≤ 75% of any duration	6, 3.9%	0, 0%	0.019
	Clinically significant episode of hypoxaemia1	32, 20.8%	1, 0.7%	< 0.001
	SpO2 < 85% of any duration	19, 12.3%	3, 2.2%	0.001

¹Clinically significant episode of hypoxemia is defined as a need to change in flow or method of oxygen delivery that the patient was originally randomised to.

HFMG: High-flow via oxygenating mouthguard; IQR: Interquartile range; SpO₂: Oxygen saturation; SNC: Standard nasal cannula.